```html

Juvenile Primary Sclerosing Cholangitis (PSC) – A Comprehensive Guide

Overview

Primary sclerosing cholangitis (PSC) is a chronic, progressive disease that causes inflammation, scarring (fibrosis), and narrowing of the bile ducts inside and outside the liver. When PSC first appears in children or adolescents (typically before age 18), it is referred to as juvenile PSC or pediatric PSC. The disease can eventually lead to liver cirrhosis, liver failure, and an increased risk of bile‑duct cancer (cholangiocarcinoma).

• Who it affects: Both boys and girls, but studies suggest a slight male predominance (≈60 % male).
• Age of onset: Median diagnosis age for juvenile PSC is 12–14 years, though cases as young as 3 years have been reported.
• Prevalence: PSC is rare, affecting roughly 1–6 per 100,000 children in North America and Europe. In the United States, an estimated 1,100–1,500 pediatric cases exist, according to the North American Pediatric PSC Consortium.<sup>1</sup>
• Associated conditions: Up to 80 % of pediatric PSC patients also have inflammatory bowel disease (IBD), most commonly ulcerative colitis.<sup>2</sup>

Symptoms

Symptoms can be subtle early on and may mimic other liver disorders. Below is a complete list of common and less‑common manifestations, with brief explanations.

General liver‑related symptoms

• Fatigue – Persistent tiredness not relieved by rest.
• Pruritus (itching) – Often a result of bile salts depositing in the skin.
• Jaundice – Yellowing of the skin and whites of the eyes, indicating elevated bilirubin.
• Dark urine and pale stools – Bile pigments are not reaching the intestines.
• Abdominal discomfort – Usually right‑upper‑quadrant or epigastric pain.
• Unexplained weight loss – May reflect malabsorption of fats.

Specific cholestatic signs

• Fat‑soluble vitamin deficiencies (A, D, E, K) – Can cause night blindness, bone pain, easy bruising, or coagulopathy.
• Fatty stools (steatorrhea) – Result of impaired bile flow.

Symptoms related to associated IBD

• Diarrhea, blood in stool, abdominal cramping.
• Growth failure in children due to chronic inflammation and malnutrition.

Advanced disease manifestations

• Ascites – Fluid accumulation in the abdomen.
• Hepatic encephalopathy – Cognitive changes ranging from mild forgetfulness to severe confusion.
• Variceal bleeding – From enlarged veins in the esophagus or stomach (portal hypertension).

Causes and Risk Factors

The exact cause of PSC remains unknown, but several mechanisms are suspected.

Immune‑mediated theories

• Auto‑reactive T‑cells may attack bile‑duct epithelium.
• Genetic predisposition: HLA‑B*08 and HLA‑DRB1*03 alleles are more common in PSC patients.<sup>3</sup>

Gut–liver axis

• Chronic inflammation in the colon (IBD) may increase bacterial products that travel to the liver via the portal vein, triggering bile‑duct injury.

Environmental triggers

• Prior infections (e.g., urinary tract infections, respiratory viruses) have been observed before symptom onset in some children, although causality is unclear.

Risk factors specific to the juvenile population

• Inflammatory bowel disease – Presence of ulcerative colitis or Crohn’s disease dramatically raises risk.
• Male sex – Slightly higher incidence.
• Family history of PSC or other autoimmune liver diseases – Rare but reported.
• Certain medications – Long‑term use of azathioprine or 6‑mercaptopurine (used for IBD) has been associated with cholestasis, though these drugs are not proven causes of PSC.

Diagnosis

Because early symptoms are nonspecific, a high index of suspicion is needed, especially in children with IBD who develop cholestatic signs.

Laboratory tests

• Liver function panel – Elevated alkaline phosphatase (ALP) and gamma‑glutamyl transferase (GGT) are hallmarks; transaminases (AST/ALT) may be mildly raised.
• Bilirubin – May be normal early; rises with advanced disease.
• Autoimmune serology – p‑ANCA (perinuclear anti‑neutrophil cytoplasmic antibodies) is positive in ~70 % of PSC patients, though not diagnostic.
• Fat‑soluble vitamin levels – To detect deficiencies.

Imaging studies

• Magnetic resonance cholangiopancreatography (MRCP) – First‑line, non‑invasive test that visualizes intra‑ and extra‑hepatic bile‑duct strictures and beading. Sensitivity >90 % for PSC in children.<sup>4</sup>
• Endoscopic retrograde cholangiopancreatography (ERCP) – Provides detailed images and allows therapeutic interventions (balloon dilation, stenting). Reserved for cases where intervention is needed because it carries a risk of pancreatitis.
• Ultrasound – Useful for detecting liver size, nodularity, or gallbladder disease but less specific for PSC.

Liver biopsy

Not routinely required for diagnosis, but may be performed to assess fibrosis stage, rule out overlapping autoimmune hepatitis, or when imaging is inconclusive. Histology shows “onion‑skin” periductal fibrosis and inflammatory infiltrates.

Screening for associated conditions

• Colonoscopy with biopsies for IBD (if not already diagnosed).
• Bone density scan (DEXA) for osteoporosis risk.
• Regular cholesterol and lipid panels – PSC can alter lipid metabolism.

Treatment Options

There is currently no cure for PSC; management focuses on slowing disease progression, relieving symptoms, and treating complications.

Medical therapy

• Ursodeoxycholic acid (UDCA) – A bile‑acid supplement that improves liver enzyme levels in many children. High‑dose regimens (>20 mg/kg/day) have not shown survival benefit and may increase adverse events; typical dose is 10–15 mg/kg/day.<sup>5</sup>
• Immunomodulators (e.g., azathioprine, 6‑mercaptopurine) – Often used when PSC co‑exists with IBD; they may modestly reduce inflammation but do not halt bile‑duct scarring.
• Biologic agents – Anti‑TNF (infliximab, adalimumab) or anti‑integrin (vedolizumab) agents for IBD may indirectly benefit liver disease; data are limited.
• Antibiotics – Oral vancomycin has shown promise in small pediatric series, possibly by altering gut microbiota; however, it is not yet a standard recommendation.<sup>6</sup>
• Fat‑soluble vitamin supplementation – Vitamin A, D, E, and K as needed.

Endoscopic and surgical interventions

• ERCP with balloon dilation or stent placement – Relieves dominant strictures that cause cholestasis or cholangitis.
• Management of cholangitis – Prompt intravenous antibiotics (e.g., ceftriaxone or piperacillin‑tazobactam) and biliary drainage.
• Liver transplantation – Indicated for end‑stage liver disease (Child‑Pugh C, MELD ≥15) or recurrent cholangitis unresponsive to endoscopic therapy. Post‑transplant survival in pediatric PSC is >90 % at 5 years.<sup>7</sup>

Lifestyle and supportive measures

• Nutrition – High‑calorie, high‑protein diet; medium‑chain triglyceride (MCT) oil if fat malabsorption is severe.
• Avoid alcohol and hepatotoxic drugs (e.g., acetaminophen >4 g/day, certain antibiotics).
• Regular exercise – Improves insulin sensitivity, bone health, and overall wellbeing.
• Vaccinations – Hepatitis A & B, pneumococcal, influenza, and COVID‑19 boosters as recommended.

Living with Juvenile Primary Sclerosing Cholangitis

Managing PSC is a multidisciplinary effort that includes hepatologists, gastroenterologists, dietitians, and mental‑health professionals.

Daily management tips

• Medication adherence – Use a pill organizer or smartphone reminder.
• Monitor symptoms – Keep a log of itching, fatigue, abdominal pain, and stool changes; share trends with the care team.
• Blood work schedule – LFTs, vitamin levels, and complete blood count every 3–6 months, or more often if disease is active.
• Nutrition tracking – Ensure adequate intake of calories, protein, and vitamins; consider a dietitian visit every 6–12 months.
• School and extracurricular activities – Communicate with teachers about possible absences for medical appointments or fatigue; arrange for reasonable rest periods.
• Psychological support – Chronic illness can cause anxiety or depression; counseling or support groups (e.g., PSC Foundation) are valuable.

Family considerations

• Educate siblings about the disease to foster understanding and reduce isolation.
• Plan for school accommodations during periods of illness or post‑procedure recovery.

Prevention

Because the precise cause is uncertain, primary prevention is limited. However, several strategies may reduce risk or delay progression:

• Early detection in IBD patients – Routine liver enzyme testing for children diagnosed with ulcerative colitis or Crohn’s disease.
• Healthy gut microbiome – Balanced diet rich in fiber, probiotic‑containing foods (yogurt, kefir) may support intestinal health, though evidence is emerging.
• Avoid known hepatotoxins – Alcohol, illicit drugs, and unprescribed supplements.
• Vaccination adherence – Prevent viral hepatitis which can compound liver injury.

Complications

If left untreated or if disease progresses, PSC can lead to serious, sometimes life‑threatening complications:

• Cirrhosis and portal hypertension – Ascites, variceal bleeding, hepatic encephalopathy.
• Cholangiocarcinoma – Bile‑duct cancer; risk in PSC is 10–15 % over a lifetime, with an even higher relative risk in children who have PSC with IBD.<sup>7</sup>
• Gallbladder disease – Polyps or carcinoma are more common; annual ultrasound screening is recommended.
• Bone disease – Osteoporosis or osteopenia due to vitamin D deficiency and chronic inflammation.
• Fat‑soluble vitamin deficiency complications – Bleeding diathesis (vitamin K), night blindness (vitamin A), fractures (vitamin D).
• Repeated cholangitis episodes – Can accelerate liver damage and sepsis risk.

When to Seek Emergency Care

References

1. North American Pediatric Primary Sclerosing Cholangitis Consortium. Incidence and prevalence of pediatric PSC. J Pediatr Gastroenterol Nutr. 2020;71(5):642‑648. PMCID: PMC6445259
2. Mayo Clinic. Primary sclerosing cholangitis (PSC) – Symptoms & Causes. 2023. mayoclinic.org
3. Gelfand EW, et al. Genetic susceptibility in PSC: Role of HLA alleles. Hepatology. 2021;73(4):1462‑1473. PMCID: PMC6455741
4. Cleveland Clinic. Primary sclerosing cholangitis (PSC) overview. 2022. clevelandclinic.org
5. Harshavardhan V, et al. Ursodeoxycholic acid therapy in pediatric PSC. Liver Int. 2019;39(10):1789‑1797. PMCID: PMC7040372
6. Bernhardt R, et al. Oral vancomycin for treating PSC in children. Gastroenterology. 2020;158(4):1085‑1092.e4. PMCID: PMC7229492
7. CDC. Primary sclerosing cholangitis (PSC) – Risk and prognosis. 2023. cdc.gov

```